|
Tuesday
|
Wednesday
|
Thursday
|
Friday
|
Saturday
|
|
TUESDAY, DECEMBER 4, 2018 |
|
8:00 am - 7:00 pm
|
REGISTRATION
- Main Lobby |
|
|
|
Pre-registered attendees can obtain materials. Those who have not yet registered may do so.
|
|
|
| 11:45 am - 1:30 pm |
WORKSHOPS |
|
| |
Molecular Biology in Breast Oncology - Hemisfair Ballroom - 3rd Level
Moderator: Carlos L. Arteaga, MD
UT Southwestern
Simmons Comprehensive Cancer Center
Dallas, TX
Novel targets in breast cancer: How to go about drugging them?
Lori S. Friedman, PhD
Genentech, Inc.
South San Francisco, CA
Circulating tumor DNA analysis to elucidate drug action & resistance
Nicholas Turner, PhD, FRCP
Institute of Cancer Research/The Royal Marsden Hospital
London, UNITED KINGDOM
The breast tumor microenvironment: Clinical implications for checkpoint inhibitors
Kornelia Polyak, MD, PhD
Dana-Farber Cancer Institute
Boston, MA
Molecular heterogeneity of TNBC: Biological implications
Samuel Aparicio, BM, BCh, PhD, FRCPath
University of British Columbia
Vancouver, CANADA
|
|
| |
|
|
| |
Clinical Research - Stars at Night Ballroom 2&3 - 3rd Level
Moderator: Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX
Phase 1 clinical trials: Is there more than 3+3?
Susan G. Hilsenbeck, PhD
Baylor College of Medicine
Houston, TX
Regulatory perspectives: Validation of molecular diagnostic assays
Reena Philip, PhD
US Food and Drug Administration
Silver Spring, MD
Incorporating patient reported outcomes and functional measures into clinical trials
Jennifer A. Ligibel, MD
Dana-Farber Cancer Institute
Boston, MA
Design of immunotherapeutic trials in breast cancer
Sherene Loi, MBBS (Hons), FRACP, PhD, FAHMS
Peter MacCallum Cancer Centre
Melbourne, AUSTRALIA
|
|
| |
|
|
| 1:30 pm - 2:00 pm |
BREAK
|
|
| |
|
|
| 2:00 pm - 7:00 pm
|
EDUCATIONAL SESSIONS - Stars at Night Ballrooms 1, 2&3, 4 and Hemisfair Ballroom - 3rd Level
Updates on advances in key areas and in technologies available for translational research. Many of these sessions will provide attendees
with a better understanding of the background leading up to talks they
will hear in the succeeding days, and some of the techniques that will
be used. These presentations should also provide researchers with ideas
and techniques to be considered for their own studies.
|
|
|
|
|
|
| 2:00 pm - 3:30 pm
|
Twenty Years of Targeting HER2: Where Are We Now? – Hemisfair Ballroom - 3rd Level
Moderator: Mothaffar F. Rimawi, MD
Baylor College of Medicine
Houston, TX
What is a HER2-positive in breast cancer in 2018?
Stuart J. Schnitt, MD
Brigham and Women's Hospital
Dana-Farber Cancer Institute
Boston, MA
Early HER2-positive breast cancer: Doing more and less
Lisa A. Carey, MD
UNC - Lineberger Comprehensive Cancer Center
Chapel Hill, NC
Advanced HER2-positive breast cancer: Overcoming treatment resistance
Mothaffar F. Rimawi, MD
Baylor College of Medicine
Houston, TX
Insights and Controversies in Metastasis Biology - Stars at Night Ballroom 1 - 3rd Level
Moderator: Michael Lewis, PhD
Baylor College of Medicine
Houston, TX
The EMT and metastasis controversy: Where things stand in 2018
Heide L. Ford, PhD
University of Colorado School of Medicine
Aurora, CO
Breast cancer's metastatic moment: How postpartum tissue involution facilitates progression
Pepper J. Schedin, PhD
Oregon Health and Science University
Portland, OR
Exosome-mediated stimulation of metastasis
Andy J. Minn, MD
University of Pennsylvania
Philadelphia, PA
Contemporary Management of Breast Cancer Brain Metastases – Stars at Night Ballroom 2&3 - 3rd Level
Moderator:
Nancy U. Lin, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
Brain metastases of breast cancer
Patricia S. Steeg, PhD
National Cancer Institute
Bethesda, MD
Multidisciplinary management of breast cancer brain metastases
Christina I. Tsien, MD
Washington University
St. Louis, MO
Systemic therapy for breast cancer brain metastases
Nancy U. Lin, MD
Dana-Farber Cancer Institute
Boston, MA
Partial Breast Irradiation - Where Does it Stand? ‐ Stars at Night Ballroom 4 - 3rd Level
Moderator: Richard Crownover, MD, PhD
UT Health San Antonio
San Antonio, TX
Partial breast irradiation: Efficacy and patient selection
Charlotte Coles, MB ChB, MRCP, FRCR, PhD
University of Cambridge
Cambridge, UNITED KINGDOM
Treatment morbidity and quality of life considerations
Timothy J. Whelan, BSc, BM, BCh, MSc, FRCPC
McMaster University
Hamilton, CANADA
Techniques and technical considerations
Frank A. Vicini, MD, FACR, FABS, FASTRO
MHP Radiation Oncology Institute
Farmington Hills, MI
|
|
|
|
|
|
| 3:45 pm - 5:15 pm
|
Late Recurrence in ER Positive Breast Cancer: Therapeutic Interventions and Biological Insights – Hemisfair Ballroom - 3rd Level
Moderator:
Matthew J. Ellis, MD, PhD
Baylor College of Medicine
Houston, TX
Tumor dormancy and recurrence
Lewis A. Chodosh, MD, PhD
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
Clinical and molecular profiles to identify who is at risk?
Mitchell Dowsett, PhD
Ralph Lauren Centre for Breast Cancer Research
London, UNITED KINGDOM
Late recurrence in ER-positive breast cancer
Julie R. Gralow, MD
University of Washington
Seattle, WA
Metabolic Reprogramming in Breast Cancer – Stars at Night Ballroom 1 - 3rd Level
Moderator: Alexander Bishop, DPhil, BSc
Greehey Children's Cancer Research Institute
UT Health San Antonio
San Antonio, TX
Oxidative stress responses in cancer
Joan S. Brugge, PhD
Harvard Medical School
Boston, MA
PI3K in breast cancer, glutamine changes and methionine addiction
Alex Toker, PhD
Beth Israel Deaconess Medical Center
Boston, MA
Systems approaches to attacking cancer vulnerabilities defined by metabolic, de-differentiation and genomic instability states
Thomas G. Graeber, PhD
University of California Los Angeles
Los Angeles, CA
Management of the Axilla after Neoadjuvant Therapy: Beyond the Clinical Trials – Stars at Night Ballroom 2&3 - 3rd Level
Moderator:
Monica Morrow, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Methods to minimize the false negative rate of sentinel lymph node surgery after neoadjuvant chemotherapy for node positive breast cancer
Judy C. Boughey, MD
Mayo Clinic
Rochester, MN
Practical approach to the axilla after neoadjuvant chemotherapy: What the clinical trials don't address
Andrea V. Barrio, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Indications for radiation treatments after neoadjuvant chemotherapy while awaiting the results of clinical trials
Thomas A. Buchholz, MD
Scripps Health
San Diego, CA
Exposures Throughout the Lifecourse - New Data on The Environment, Hormones, and Alcohol - Stars at Night Ballroom 4 - 3rd Level
Moderator: Melissa L. Bondy, PhD
Baylor College of Medicine
Houston, TX
Windows of susceptibility across the lifecourse and breast cancer
Lawrence H. Kushi, ScD
Kaiser Permanente Northern California
Oakland, CA
New data on hormones and risk of breast cancer
Susan E. Hankinson, ScD
University of Massachusetts
Amherst, MA
Does breast cancer prevention need an 18th amendment? New evidence on alcohol and breast cancer
Mary Beth Terry, PhD
Columbia University
New York, NY
|
|
|
|
|
|
| 5:30 pm - 7:00 pm
|
Updates in the Treatment of Triple Negative Breast Cancer - Hemisfair Ballroom - 3rd Level
Moderator:
Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX
Optimizing treatment of early stage triple negative breast cancer: Clinical challenges and new scientific horizons
Angela DeMichele, MD, MSCE
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA
Updates on immunotherapy for TNBC
Sylvia Adams, MD
New York University
New York, NY
Triple negative breast cancer: Current and future directions in metastatic patients
Jenny C. Chang, MD
Houston Methodist Hospital
Houston, TX
Translational Insights in Estrogen Receptor Signaling and Endocrine Resistance - Bench to Bedside – Stars at Night Ballroom 1 - 3rd Level
Moderator:
Rachel Schiff, PhD
Baylor College of Medicine
Houston, TX
Recurrent ESR1 mutations activating mutations in breast cancer
Rinath M. Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, MA
Mining noncoding mutations for drivers of development in ER alpha-positive breast cancer
Mathieu Lupien, PhD
Princess Margaret Cancer Centre
Toronto, CANADA
Blockade of estrogen signaling boosts antitumor immunity by inhibiting tumor-induced pathological myelopoiesis
Jose Conejo-Garcia, MD, PhD
H. Lee Moffitt Cancer Center
Tampa, FL
Managing Lymphedema in 2018: Can We Forgo the Sleeve?- Stars at Night Ballroom 2&3 - 3rd Level
Moderator:
Bhuvaneswari Ramaswamy, MBBS, MRCP
Ohio State University
Columbus, OH
Lymphedema management in 2018: Are we making any progress?
Babak J. Mehrara, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Current status of diagnosis, monitoring, and non-surgical management of lymphedema
Sarah A. McLaughlin, MD
Mayo Clinic
Jacksonville, FL
Microsurgical treatment of lymphedema
David W. Chang, MD, FACS
University of Chicago
Chicago, IL
BRCA 1/2: Beyond DNA Repair - Stars at Night Ballroom 4 - 3rd Level
Moderator: Ratna K. Vadlamudi, PhD
UT Health San Antonio
San Antonio, TX
BRCA2 and control of transcription: R-loop dynamics
Ashok Venkitaraman, MBBS, PhD
MRC Cancer Unit
University of Cambridge
Cambridge, UNITED KINGDOM
Link between BRCA1 and Pol II pausing in mammary gland development and tumorigenesis
Rong Li, PhD
UT Health San Antonio
San Antonio, TX
BRCA 1/2/3 and p53 in replication fork stability
Katharina Schlacher, PhD
UT MD Anderson Cancer Center
Houston, TX
|
|
| |
|
|
| 7:30 pm - 10:00 pm |
OPEN SATELLITE EVENT presented by Research to Practice - Marriott Rivercenter
Addressing Current Questions and Controversies in the Management of Early and Advanced Breast Cancer
For more information and to register for this event, please click on the link below:
http://www.researchtopractice.com/Meetings/SA2018
|
|
|
|